Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide - Abstract

Although many treatments have been applied to treat hormone-refractory prostate cancer (HRPC), therapeutic outcome is not altogether satisfactory.

In the case of locally recurring HRPC, uncontrolled gross hematuria, dysuria, and scalding are often experienced. We report a patient who improved following intra-arterial infusion of cisplatin (CDDP) and ifosfamide (IFM) to treat urinary retention caused by locally recurring HRPC. After chemotherapy, cancer volume was remarkably reduced and symptoms improved.

 

Written by:
Uemura K, Nishihara K, Hayashi T, Tomiyasu K, Matsuoka K.   Are you the author?
Department of Urology, Kurume University School of Medicine, Asahimach 67, Kurume, Fukuoka, Japan.

Reference: J Infect Chemother. 2011 Dec 28. Epub ahead of print.
doi: 10.1007/s10156-011-0352-9

PubMed Abstract
PMID: 22203121

UroToday.com Prostate Cancer Section

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe